The Biosimilar CT-P6 Exhibits Equivalent Safety and Efficacy Compared With Trastuzumab for HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CT-P6 Compared With Reference Trastuzumab for HER2-Positive Breast Cancer: A Randomised, Double-Blind, Active-Controlled, Phase 3 Equivalence Trial
Lancet Oncol 2017 Jun 02;[EPub Ahead of Print], J Stebbing, Y Baranau, V Baryash, A Manikhas, V Moiseyenko, G Dzagnidze, E Zhavrid, D Boliukh, D Stroyakovskii, J Pikiel, A Eniu, D Komov, G Morar-Bolba, RK Li, A Rusyn, SJ Lee, SY Lee, FJ EstevaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.